摘要
目的评价老年广泛期小细胞肺癌(small cell lung cancer,SCLC)患者一线EP或EC方案化疗的疗效和安全性。方法回顾性收集并分析2016年6月至2017年12月在我院行一线EP或EC方案化疗的老年广泛期SCLC的临床数据。结果共116例,EP方案47例,EC方案69例,EP方案组的平均年龄明显低于EC组[(68.33±8.35)vs.(74.21±9.17),P=0.0006],EP和EC组的ORR分别为51.06%和49.28%,DCR为87.23%和85.51%,mTTP分别为5.9个月和5.7个月,差异均无统计学意义(P>0.05);EC组的Ⅲ-Ⅳ度粒细胞减少和血小板减低的发生率较高,为31.88%和8.70%,EP组为23.40%和4.26%,但两组差异无统计学意义(P>0.05)。两组的治疗相关性毒性差异无统计学意义,EP组的肾损伤发生率为2.13%,EC组为1.45%,两组患者的肝损伤发生率分别为12.77%和10.14%(P>0.05)。结论老年广泛期SCLC患者较多采用EC方案化疗,EP和EC方案的疗效近似,且比较安全,EC方案的血液学毒性较重,两方案的肝损伤需引起重视。
Objective To evaluate the efficacyand safety of etoposide plus cisplatin(EP)andetoposide plus carboplatin(EC)regime in elderly patients with extensive-stage small-cell lung cancer.Methods This′s a retrospective study.Elderly patients with extensive-stage small cell lung cancer who undergone EP or EC regime chemotherapy and had complete efficacy and toxicity records were enrolled and were analyzed from June 2016 to December 2017.Results 116 cases were collected.47 were with EP and 69 with EC regime chemotherapy.The mean age of EP group was significantly lower than EP group(68.33±8.35 vs.74.21±9.17,P=0.0006).Objective response rate(ORR)of EP and EC group were 51.06%and 49.28%,disease control rare(DCR)were 87.23%and 85.51%respectively.The ORR and DOR were similar and with no significant difference between the 2 groups.In addition,the mean time to progression(mTTP)were 5.9 month and 5.7 month of the two groups and were also without significant difference(P>0.05).The toxicity of the two group were similar and the grade 3/4 leucopenia and thrombocytopeniaof EC group were 31.88%and 8.70%which were higher than EP group(23.40%and 4.26%),but with no significant difference(P>0.05).Renal injury of EP and EC group was 2.13%and 1.45%.Hepatic impairment were more common in two groups and were 12.77%and 10.14%of the EP and EC group(P>0.05).Conclusion Compared with EP regime,EC regime was more applied in elderly patients with extensive-stage of small cell lung cancer.The efficacy and safety of the two regime are similar.Hematological toxicities are more severe in the EC group and the hepatic toxicity should be valued in all patients in the two groups.
作者
高峰
刘徳军
张宪伟
张博然
GAO Feng;LIU Dejun;ZHANG Xianwei;ZHANG Boran(Health Service Department of the Guard-Bureau of the General office of the Central Committee of the Communist Party of China,Beijing 110000,China)
出处
《实用医学杂志》
CAS
北大核心
2020年第18期2555-2558,共4页
The Journal of Practical Medicine
关键词
老年患者
广泛期小细胞肺癌
化疗疗效
毒性
elderly patient
extensive-stage of SCLC
chemotherapy
efficacy and toxicity
